ELIZABETH YAKABOSKI

Allopathic & Osteopathic Physicians|Allergy & Immunology CHELMSFORD, MA NPI 1134583560

General Payments — all program years on this page

$1,703.09

  • Category: General Payments
  • Program years: PY2021–2024
  • Record count: 93
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $466.97 across 21 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $466.9721

By paying entity

Latest program year (PY2024) · sorted by reported total.

By program year

Program yearAmountRecords
2021 $49.903
2022 $199.2110
2023 $987.0159
2024 $466.9721

Records — PY2024 (21)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1087426450 Novartis Pharmaceuticals Corporation $14.27 02/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104278755 AstraZeneca Pharmaceuticals LP $14.98 04/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104675399 AstraZeneca Pharmaceuticals LP $26.79 04/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104704537 AstraZeneca Pharmaceuticals LP $24.39 02/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105447617 AstraZeneca Pharmaceuticals LP $13.33 04/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1111743484 Amgen Inc. $16.70 02/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1114258097 Regeneron Healthcare Solutions, Inc. $29.89 02/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1115904042 GlaxoSmithKline, LLC. $24.49 01/19/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116458489 GlaxoSmithKline, LLC. $16.34 05/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116536432 GlaxoSmithKline, LLC. $19.54 04/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117470590 BioCryst US Sales Co., LLC $13.31 03/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117478382 BioCryst US Sales Co., LLC $17.90 03/28/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1126624420 kaleo, Inc. $29.47 01/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1126624422 kaleo, Inc. $23.66 02/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1126624424 kaleo, Inc. $23.59 04/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1126624426 kaleo, Inc. $26.87 03/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1127503975 Hikma Pharmaceuticals USA $22.11 02/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1134609799 CSL Behring $20.61 01/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137700288 Takeda Pharmaceuticals U.S.A., Inc. $15.97 01/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1140013515 GENZYME CORPORATION $41.49 01/25/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1140013521 GENZYME CORPORATION $31.27 01/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.